Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Has Consensus Target Price of $122.00

Monopar Therapeutics Inc. (NASDAQ:MNPR) has received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $122.00.

MNPR has been the topic of a number of analyst reports. HC Wainwright boosted their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald cut Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Barclays reiterated an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Finally, BTIG Research boosted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th.

Monopar Therapeutics Stock Up 6.2%

MNPR opened at $71.42 on Thursday. The company has a market capitalization of $479.23 million, a price-to-earnings ratio of -32.91 and a beta of 1.62. The firm has a 50-day moving average price of $86.88 and a 200-day moving average price of $77.39. Monopar Therapeutics has a twelve month low of $50.07 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts expect that Monopar Therapeutics will post -2.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the transaction, the director owned 23,751 shares of the company’s stock, valued at $2,654,649.27. The trade was a 11.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of Monopar Therapeutics stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the transaction, the chief executive officer directly owned 99,267 shares of the company’s stock, valued at $8,735,496. The trade was a 22.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock worth $4,527,913 in the last 90 days. 9.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently modified their holdings of MNPR. Your Advocates Ltd. LLP bought a new stake in Monopar Therapeutics during the 1st quarter worth approximately $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the 1st quarter valued at $250,000. Sei Investments Co. grew its position in shares of Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after purchasing an additional 656 shares in the last quarter. Bank of America Corp DE grew its position in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter valued at $3,458,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.